Italy, Dec. 6 -- Project Id: 77604
Description: Grant agreement ID: 843585
Status
Ongoing project
Start date
1 July 2019
End date
30 June 2021
Funded under:
H2020-EU.1.3.2.
Overall budget:
€ 171 473,28
EU contribution
€ 171 473,28
Objective
Pulmonary Arterial Hypertension (PAH) is a life-threatening condition; even if treated, patients only have a 5-year survival rate of less than 60%. For the treatment of PAH, Chiesi Pharmaceuticals develops Rho-associated, coiled-coil-containing protein kinase (ROCK) inhibitors.
The aim of this project is to elucidate conformational changes in ROCK in vitro as well as in the cellular environment that are induced by anti-PAH drug candidates, which are currently being tested in p...